The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
Abstract
The p53 protein can inhibit cell cycling or induce apoptosis, and is thus a critical regulator of tumorigenesis. This protein is negatively regulated by a physical interaction with MDM2, an E3 ubiquitin ligase. This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a p53-dependent manner. The recently discovered MDM2-related protein MDM4 (also known as MDMX) has some of the same properties as MDM2. MDM4 binds and inhibits p53 transcriptional activity in vitro. Unlike MDM2, however, MDM4 does not cause nuclear export or degradation of p53 (refs. 9,10). To study MDM4 function in vivo, we deleted Mdm4 in mice. Mdm4-null mice died at 7.5-8.5 dpc, owing to loss of cell proliferation and not induction of apoptosis. To assess the importance of p53 in the death of Mdm4-/- embryos, we crossed in the Trp53-null allele. The loss of Trp53 completely rescued the Mdm4-/- embryonic lethality. Thus, MDM2 and MDM4 are nonoverlapping critical regulators of p53 in vivo. These data define a new pathway of p53 regulation and raise the possibility that increased MDM4 levels and the resulting inactivation of p53 contribute to the development of human tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mice lacking Mdm4 exhibit embryonic lethal phenotypes that are also completely rescued by p53 deletion (Finch, et al., 2002; Migliorini, et al., 2002; Parant, et al., 2001).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Parant, et al., 2001
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [108]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [108]
In the citing paper
“Several studies showed that MDMX-null mice also die in utero in a p53-dependent fashion, which can be rescued by crossing into the p53-null background (Finch et al, 2002;Migliorini et al, 2002;Parant et al, 2002).”
From ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage (2005) · cites this paper as Parant et al, 2002
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“gif" NDATA ITEM> ]> The p53 protein can inhibit cell cycling or induce apoptosis, and is thus a critical regulator of tumorigenesi”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“This protein is negatively regulated by a physical interaction with MDM2, an E3 ubiquitin ligas”
BackgroundTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain
McMahon, A. P., & Bradley, A. (1990) · Cell · doi:10.1016/0092-8674(90)90385-r · Cited by 1,540
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a p53-dependent manne”
BackgroundSelf-citationRescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1×
“This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a p53-dependent manne”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–521 of 521
Das Onkoprotein Mdm4 und seine Wirkung auf die DNA-Replikation
Wohlberedt, K. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10645
Oncogenic and teratogenic effects of p53Y217C, a mouse model of the human hotspot mutant p53Y220CPreprint
Jaber, S., Eldawra, E., Rakotopare, J., Gabriel, M., Lejour, V., Simeonova, I., Morillon, A., Bardot, B., & Toledo, F. (2024) · eLife · doi:10.7554/elife.102434.1
Jaber, S., Eldawra, E., Rakotopare, J., Simeonova, I., Lejour, V., Gabriel, M., Cañeque, T., Volochtchouk, V., Licaj, M., Fajac, A., et al. (2025) · eLife · doi:10.7554/elife.102434.2
Targeting the p53/MDM2 Pathway for Cancer Therapy
Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2
Pathophysiological impact of targeting the ROS-p53 axis
Sayin, V. I. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Sanford, J. D., Yang, J., Han, J., Tollini, L. A., Jin, A., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16664347
MDM4 at the Crossroads: Beyond p53 and MDM2
Thapa, D., John, A. S., Parrales, A., Ranjan, A., & Iwakuma, T. (2026) · Cancers · doi:10.3390/cancers18071059
Malhab, L. J. B. (2016) · theses.fr (ABES) · doi:10.70675/a9a79207z0857z4ed5zb207z749cdceb9430
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Toufektchan, E. (2018) · theses.fr (ABES) · doi:10.70675/58dfec7cz94b0z449fz96a6z9051bf80c551
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Durand, R. (2020) · theses.fr (ABES) · doi:10.70675/6ccc120bz65f7z4c6czabf5z9bea26651b66
Rakotopare, J. (2024) · theses.fr (ABES) · doi:10.70675/cc79cc10zbaf8z4e88za003z8a8d37707576
Mdm2-p53 Signaling in Tissue Homeostasis and the DNA Damage Response: A Dissertation
Gannon, H. (2012) · eScholarship@UMassChan · doi:10.13028/sfjc-xh51
Metadata
- Authors
- Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Leiden University Medical Center (NL)
- Corresponding author
- Lozano, Guillermina
- Venue
- Nature Genetics
- Published
- 2001-08-20
- Volume
- 29
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1598779357
- Cited by
- 517
- References
- 19
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 14 · 2018: 15 · 2017: 22 · 2016: 34 · 2015: 14 · 2014: 35 · 2013: 18 · 2012: 23
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- MDM4, MDM2, p53 regulation, Trp53, embryonic lethality, cell proliferation, E3 ubiquitin ligase, tumor suppressor, p53 inactivation
- MeSH terms
- Animals, Base Sequence, Embryo, Mammalian, Genes, Lethal, Nuclear Proteins, Precipitin Tests, Proto-Oncogene Proteins, Blotting, Western, Polymerase Chain Reaction, Genes, p53, Tumor Suppressor Protein p53, DNA Primers, Mice, Knockout, In Situ Nick-End Labeling, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
